Revised SPC: Mysimba 8 mg/90 mg (naltrexone/bupropion) prolonged-release tablets

SPC updated to note there have been post-marketing reports of serotonin syndrome when naltrexone/bupropion was co-administered with a serotonergic agent, such as SSRIs or SNRIs, and that post-marketing cases of hypertensive crisis have been reported during the initial titration.

Source:

electronic Medicines compendium